We are the biospecimen and biomarker specialists™
Discovery Life Sciences combines the world’s largest biospecimen inventory and procurement network with preeminent multi-omic service laboratories to accelerate precision medicine programs for cancer, infectious disease, and other complex conditions.
Our robust biospecimen and biomarker platform is optimized for speed and large scale capacity. We routinely manage hundreds of studies and expertly test thousands of biospecimens simultaneously as a single vendor - eliminating time consuming and inefficient transfers of biospecimens or data between different vendors. Leading biopharma, diagnostic and academic institutions trust us to quickly deliver high-quality biospecimens and reliable, reproducible biomarker data, so they can outpace their competition and push the leading edge of innovation.
We accomplish this with a biobank of over 10 million biospecimens and hundreds of clinical sites that allow researchers to build bespoke study cohorts and seamlessly interrogate them using our CLIA certified, GLP compliant service laboratories, including our world-renowned sequencing and bioinformatics laboratory, HudsonAlpha Discovery, the expert IHC service laboratory that built the pembrolizumab companion diagnostic prototype, and extensive cell and flow cytometry facilities with GMP compliant leukapheresis products for cell therapy development and manufacturing.
Visit www.dls.com to learn more.
Discovery Life Sciences combines the world’s largest biospecimen inventory and procurement network with preeminent multi-omic service laboratories to accelerate precision medicine programs for cancer, infectious disease, and other complex conditions.
Our robust biospecimen and biomarker platform is optimized for speed and large scale capacity. We routinely manage hundreds of studies and expertly test thousands of biospecimens simultaneously as a single vendor - eliminating time consuming and inefficient transfers of biospecimens or data between different vendors. Leading biopharma, diagnostic and academic institutions trust us to quickly deliver high-quality biospecimens and reliable, reproducible biomarker data, so they can outpace their competition and push the leading edge of innovation.
We accomplish this with a biobank of over 10 million biospecimens and hundreds of clinical sites that allow researchers to build bespoke study cohorts and seamlessly interrogate them using our CLIA certified, GLP compliant service laboratories, including our world-renowned sequencing and bioinformatics laboratory, HudsonAlpha Discovery, the expert IHC service laboratory that built the pembrolizumab companion diagnostic prototype, and extensive cell and flow cytometry facilities with GMP compliant leukapheresis products for cell therapy development and manufacturing.
Visit www.dls.com to learn more.
Location: United States, Alabama, Huntsville
Employees: 501-1000
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | Water Stre... | waterstree... |
Mentions in press and media 11
| Date | Title | Description |
| 24.03.2026 | Discovery Life Sciences and Mindpeak Partner to Bring AI Precision to Cancer Biomarker Testing in Global Clinical Trials | New alliance takes aim at inconsistent biomarker interpretation across pathologists, a persistent challenge in drug development HUNTSVILLE, Ala. and HAMBURG, Germany, March 24, 2026 /PRNewswire/ -- Inconsistent biomarker interpretation acro... |
| 24.10.2022 | Applications of Cryopreserved Human Dissociated Tumor Cells (DTCs) for Drug and Diagnostic Development, Upcoming Webinar Hosted by Xtalks | These specimens provide the opportunity to screen for novel biomarker expressions including the expression patterns of the programmed cell death protein-1/ programmed cell death ligand-1 (PD1/PDL1) pathway. TORONTO (PRWEB) October 24, 2022 ... |
| 11.10.2022 | Leveraging Clinical Trial Ready IHC Assays from Target Validation to Prospective Enrollment and CDx Development, Upcoming Webinar Hosted by Xtalks | A critical aspect of target validation includes developing robust assays to accurately reflect expression in the intended to treat populations. TORONTO (PRWEB) October 11, 2022 Many clinical trials fail due to inadequately distinguishing be... |
| 04.10.2022 | Metabolism-Dependent Cytotoxicity Assay (MDCA) for the Evaluation of the DILI Potential of Drug Candidates, Upcoming Webinar Hosted by Xtalks | The featured speaker will review the role of metabolic activation and detoxification in drug toxicity as well as to introduce a novel in vitro experimental system, the metabolism-dependent cytotoxicity assay (MDCA) for the evaluation of the... |
| 08.03.2022 | Predictive and Pharmacodynamic Biomarker Profiling to Conserve Precious Clinical Trial Samples, Upcoming Webinar Hosted by Xtalks | Common obstacles to completing biomarker profiling studies, especially in retrospective exploratory biomarker research, are the lack of sufficient sample volume and reduced quality of formalin-fixed, paraffin-embedded (FFPE) samples and oth... |
| 03.12.2021 | Biospecimen M&A: Discovery acquires Albert Li's hepatocyte project; PhIII trial on Bayer's Nubeqa reached primary endpoint | Discovery Life Sciences has acquired what claims to be the Maryland-based host of the world’s largest hepatocyte inventory, known as IVAL, to help researchers select more effective and safer drug candidates in the future. ... |
| 16.11.2021 | Discovery Life Sciences Selects Othram as Forensic Casework Commercialization Partner | THE WOODLANDS, Texas (PRWEB) November 16, 2021 Othram Inc., the leading forensic sequencing laboratory for law enforcement, and Discovery Life Sciences™ (Discovery), the biospecimen and biomarker specialists™, today announced their partners... |
| 27.07.2021 | Benchmark Research Announces New Organizational Structure and Advisory Board | AUSTIN, Texas (PRWEB) July 27, 2021 The new advisory board that will support Benchmark in upcoming ventures this year is made up of a talented team of masterful industry experts including John Farinacci, Glenn Bilawsky, and Karen Skelton. J... |
| 18.05.2021 | Discovery Life Sciences Acquires Targos To Create Market-Leading Global Tissue Biomarker Services USA - English France - Français Deutschland - Deutsch España - español Slovensko - sloven�ina Lat... | |
| 12.11.2020 | Discovery Life Sciences Launches TruSight Oncology 500 (TSO500) Solid Tumor FFPE and cfDNA Services to Advance Liquid Biopsy Development and Immunotherapy Clinical Research USA - English Polska - Po... |
Show more